Oaktree Acquisition Corp. III Life Sciences (OACCW) Common Equity (2024 - 2026)

Oaktree Acquisition Corp. III Life Sciences' Common Equity history runs 3 years deep, the most recent figure standing at -$7.2 million for Q1 2026.

• Quarterly Common Equity fell 10.85% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.2 million (down 10.85% YoY) and the FY2025 annual result came in at -$6.8 million, down 11.45% from the prior year.
• Common Equity was -$7.2 million for Q1 2026 at Oaktree Acquisition Corp. III Life Sciences, down from -$6.8 million in the prior quarter.
• Across five years, Common Equity topped out at -$6.1 million in Q4 2024 and bottomed at -$7.2 million in Q1 2026.
• A 3-year average of -$6.6 million and a median of -$6.7 million in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2025 — Common Equity retreated 11.45% — and 2026, when it slipped 10.85%.
• Oaktree Acquisition Corp. III Life Sciences' Common Equity stood at -$6.1 million in 2024, then declined by 11.45% to -$6.8 million in 2025, then dropped by 6.74% to -$7.2 million in 2026.
• Business Quant data shows OACCW's Common Equity at -$7.2 million in Q1 2026, -$6.8 million in Q4 2025, and -$6.8 million in Q3 2025.